Investor Relations

Company Overview

Virax Biolabs is a Biotech and disruptive Medical Technology company focused on the prevention, detection and diagnosis of Viral threats. Our mission is the global provision of high-quality diagnostic kits, particularly T-Cell tests, which accurately and effectively predict an individual's immune response to significant viral threats. Our proprietary diagnostic T-cell technologies are virus agnostic, offering high levels of transparency, information and insight in a cost-efficient way. Key product ranges include ViraxClear, ViraxCare and flagship product being released 2022, Virax Immune.

IR Contacts


Virax Biolabs Group Limited
30 Broadwick Street
London W1F 8JB
United Kingdom
T: +44 20 7788 7414

Investor Relations

Skyline Corporate Communications Group, LLC
Scott Powell
One Rockefeller Plaza
11th Floor
New York, NY 10020
M: 646-893-5835

Transfer Agent

Continental Stock Transfer
Charlotte Hewitt
1 State Street
30th Floor
New York, NY 10004
T: 212-857-7577